ArticleJournal of dermatological case reports2010
Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy.
Article in Journal of dermatological case reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review.Archives of dermatological research · 2022Pooled it
- Comparison of Current International Guidelines for the Management of Alopecia Areata-Comprehensive Review.International journal of molecular sciences · 2025Review
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology.Frontiers in immunology · 2025Review
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions.Frontiers in immunology · 2023Review
- Successful treatment of concomitant alopecia universalis and Crohn's disease with upadacitinib: A case report.SAGE open medical case reports · 2023Article
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.Clinical reviews in allergy & immunology · 2021Review
- Comparison of serum concentrations of interleukins 10, 12, 17 and 35 between patients with alopecia areata and controls.Postepy dermatologii i alergologii · 2021Article
- Alopecia Areata: An Autoimmune Disease of Multiple Players.ImmunoTargets and therapy · 2021Review
- Ixekizumab-induced alopecia areata.JAAD case reports · 2020Article
- Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata.JAAD case reports · 2017Article
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.Advances in therapy · 2017Review
- Bullous pemphigoid during ustekinumab therapy.JAAD case reports · 2015Article
- Alternaria scalp infection in a patient with alopecia areata. Coexistence or causative relationship?Journal of dermatological case reports · 2012Article
- Transient Efficacy of Tofacitinib in Alopecia Areata Universalis.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUstekinumab is a new immunosuppressive anti-psoriasis agent. The drug targets the p40 subunit of IL-12 and IL-23 and indirectly inhibits cytokine production by Th17 cells. MAIN OBSERVATIONS: We present a case of a 36-year-old male patient with psoriasis, who received ustekinumab therapy, applied in 45mg subcutaneous injections at week 0, 4 and than every 12 weeks. After 7 months of therapy PASI decreased from 10,1 to 0,9. At this phase of therapy he developed two patches of alopecia areata on the scalp. The diagnosis was made based on clinical appearance and was confirmed by trichoscopy (hair and scalp dermoscopy) and reflectance confocal microscopy. The development of alopecia areata was preceded by emotional stress and dental infection.
conclusionsUstekinumab seems an unlikely cause of alopecia areata in this patient. However, lack of efficacy is preventing hair loss may indicate that interleukin- 12 cytokine family is not a key player in pathogenesis of alopecia areata.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.